IQVIA Holdings Inc. (IQV) stock
IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 9/3014% above fair value
$257.60−7.13 (-2.69%)
Close on Nov 17, 2026Market cap $42.45BP/E 31.3Yield –
Iqvia total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Iqvia's total debt was $16.07B at Sep 30, 2026. For fiscal 2025 it was $15.72B, up 12.5% from the year before. Over ten years it grew 20.3% a year on average. The highest annual figure on record is $15.72B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.72B | +12.5% |
| FY2024 | Dec 31, 2024 | $13.98B | +2.3% |
| FY2023 | Dec 31, 2023 | $13.67B | +7.3% |
| FY2022 | Dec 31, 2022 | $12.75B | +5.1% |
| FY2021 | Dec 31, 2021 | $12.13B | -3.3% |
| FY2020 | Dec 31, 2020 | $12.53B | +7.6% |
| FY2019 | Dec 31, 2019 | $11.65B | +5.8% |
| FY2018 | Dec 31, 2018 | $11.01B | +7.6% |
| FY2017 | Dec 31, 2017 | $10.23B | +42.0% |
| FY2016 | Dec 31, 2016 | $7.20B | +191.7% |
| FY2015 | Dec 31, 2015 | $2.47B | +8.1% |
| FY2014 | Dec 31, 2014 | $2.28B | +11.6% |
| FY2013 | Dec 31, 2013 | $2.05B | -15.5% |
| FY2012 | Dec 31, 2012 | $2.42B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $16.07B | +7.4% |
| Q2 FY2026 | Jun 30, 2026 | $16.00B | +3.3% |
| Q1 FY2026 | Mar 31, 2026 | $15.83B | +10.5% |
| Q4 FY2025 | Dec 31, 2025 | $15.72B | +12.5% |
| Q3 FY2025 | Sep 30, 2025 | $14.96B | +10.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.49B | +16.8% |
| Q1 FY2025 | Mar 31, 2025 | $14.33B | +5.9% |
| Q4 FY2024 | Dec 31, 2024 | $13.98B | +2.3% |
| Q3 FY2024 | Sep 30, 2024 | $13.51B | -0.9% |
| Q2 FY2024 | Jun 30, 2024 | $13.26B | -3.8% |
| Q1 FY2024 | Mar 31, 2024 | $13.54B | +2.7% |
| Q4 FY2023 | Dec 31, 2023 | $13.67B | +7.3% |
| Q3 FY2023 | Sep 30, 2023 | $13.63B | +10.0% |
| Q2 FY2023 | Jun 30, 2023 | $13.78B | +7.9% |
| Q1 FY2023 | Mar 31, 2023 | $13.18B | +4.3% |
| Q4 FY2022 | Dec 31, 2022 | $12.75B | +5.1% |
| Q3 FY2022 | Sep 30, 2022 | $12.39B | +1.8% |
| Q2 FY2022 | Jun 30, 2022 | $12.77B | +3.9% |
| Q1 FY2022 | Mar 31, 2022 | $12.64B | +3.3% |
| Q4 FY2021 | Dec 31, 2021 | $12.13B | -3.3% |
| Q3 FY2021 | Sep 30, 2021 | $12.17B | -1.4% |
| Q2 FY2021 | Jun 30, 2021 | $12.29B | +1.5% |
| Q1 FY2021 | Mar 31, 2021 | $12.24B | +1.7% |
| Q4 FY2020 | Dec 31, 2020 | $12.53B | +7.6% |
| Q3 FY2020 | Sep 30, 2020 | $12.34B | +6.9% |
| Q2 FY2020 | Jun 30, 2020 | $12.11B | +6.2% |
| Q1 FY2020 | Mar 31, 2020 | $12.03B | +6.6% |
| Q4 FY2019 | Dec 31, 2019 | $11.65B | +5.8% |
| Q3 FY2019 | Sep 30, 2019 | $11.54B | +8.7% |
| Q2 FY2019 | Jun 30, 2019 | $11.40B | +6.3% |
| Q1 FY2019 | Mar 31, 2019 | $11.29B | +8.1% |
| Q4 FY2018 | Dec 31, 2018 | $11.01B | +7.6% |
| Q3 FY2018 | Sep 30, 2018 | $10.62B | +8.9% |
| Q2 FY2018 | Jun 30, 2018 | $10.73B | +19.8% |
| Q1 FY2018 | Mar 31, 2018 | $10.45B | +25.2% |
| Q4 FY2017 | Dec 31, 2017 | $10.23B | +42.0% |
| Q3 FY2017 | Sep 30, 2017 | $9.75B | – |
| Q2 FY2017 | Jun 30, 2017 | $8.95B | – |
| Q1 FY2017 | Mar 31, 2017 | $8.35B | – |
| Q4 FY2016 | Dec 31, 2016 | $7.20B | – |
See a number that looks wrong?